Page last updated: 2024-11-07

mci 154

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MCI 154: structure given in UD 38:41n [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123941
CHEMBL ID543966
MeSH IDM0148314

Synonyms (24)

Synonym
mci-154
senazodan hydrochloride
6-(4-(4'-pyridyl)aminophenyl)-4,5-dihydro-3(2h)-pyridazinone hydrochloride
mci 154
3(2h)-pyridazinone, 4,5-dihydro-6-(4-(4-pyridinylamino)phenyl)-, monohydrochloride
4,5-dihydro-6-(4-(4-pyridinylamino)phenyl)-3(2h)-pyridazinone monohydrochloride
CHEMBL543966
98326-33-1
unii-8aqj5mim3p
8aqj5mim3p ,
3(2h)-pyridazinone, 4,5-dihydro-6-(4-(4-pyridinylamino)phenyl)-, hydrochloride (1:1)
AKOS030558030
6-{4-[(pyridin-4(1h)-ylidene)amino]phenyl}-4,5-dihydropyridazin-3-ol--hydrogen chloride (1/1)
DTXSID00913328
senazodan hcl
3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1h-pyridazin-6-one;hydrochloride
Q27270120
MS-24374
6-(4-(pyridin-4-ylamino)phenyl)-4,5-dihydropyridazin-3(2h)-one hydrochloride
HY-101693A
senazodan (hydrochloride)
CS-0033842
3(2h)-pyridazinone, 4,5-dihydro-6-[4-(4-pyridinylamino)phenyl]-, monohydrochloride
mci 154 (hydrochloride)

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Compared with the normal control group, the cumulative dose-response curve of SMA to Ca2+ in shock group was shifted to the right, the maximal contraction to Ca2+ was decreased significantly (P<0."( [Effect of MCI-154 on calcium sensitivity of vascular smooth muscle and its mechanism in hemorrhagic shock in rats].
Liu, LM; Yang, GM, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID60280Inotropic activity determined by evaluating the % change in Diastolic Blood Pressure (DBP) at a dose of 3 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID59137Positive inotropic in the isolated papillary muscle of the dog.1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60150Inotropic activity determined by evaluating the % change in contractile force (CF) of right ventricle at a dose of 3 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60153Inotropic activity determined by evaluating the % change in Cardiac out put (CO)at a dose of 10 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60149Inotropic activity determined by evaluating the % change in contractile force (CF) of right ventricle at a dose of 30 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID61605Inotropic activity determined by evaluating the maximum rate of rise in left ventricular pressure at a dose of 10 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID61742Inotropic activity determined by evaluating the maximum rate of rise in left ventricular pressure at a dose of 3 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60291Inotropic activity determined by evaluating the % change in Systolic Blood Pressure (SBP) at a dose of 10 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60287Inotropic activity determined by evaluating the % change in Heart Rate (HR) at a dose of 3 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60279Inotropic activity determined by evaluating the % change in Diastolic Blood Pressure (DBP) at a dose of 30 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60294Inotropic activity determined by evaluating the % change in Systolic Blood Pressure (SBP) at a dose of 30 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID61741Inotropic activity determined by evaluating the maximum rate of rise in left ventricular pressure at a dose of 30 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60146Inotropic activity determined by evaluating the % change in contractile force (CF) of right ventricle at a dose of 10 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID59298Positive inotropic activity determined in the isolated papillary muscle of the dog(that produced 30% increase in dose- response curves [dP/dt(max)])1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60286Inotropic activity determined by evaluating the % change in Heart Rate (HR) at a dose of 30 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60156Inotropic activity determined by evaluating the % change in Cardiac out put (CO)at a dose of 30 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60157Inotropic activity determined by evaluating the % change in Cardiac out put (CO)at a dose of 3 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60295Inotropic activity determined by evaluating the % change in Systolic Blood Pressure (SBP) at a dose of 3 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60160Inotropic activity determined by evaluating the % change in Diastolic Blood Pressure (DBP) at a dose of 10 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60283Inotropic activity determined by evaluating the % change in Heart Rate (HR) at a dose of 10 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (26.15)18.7374
1990's35 (53.85)18.2507
2000's13 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.25 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.54%)5.53%
Reviews6 (9.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other58 (89.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]